Maintaining expectation of a FY24 total revenue decline of a low-single digit percentage versus FY23, with core pharmaceutical revenue expected to be roughly flat versus full year 2023. Now expects operating income to grow at a high-teen percentage versus full year 2023 with maintained expectation of a mid-single digit percentage operating margin improvement.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter